The art of proteomics translation  by Sanchez, Jean-Charles
ET
A
ﬁ
P
s
n
t
a
a
t
t
c
a
t
d
a
w
p
d
p
b
m
c
t
m
a
t
e
t
c
a
t
t
pt r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 1–2
Available  online  at  www.sciencedirect.com
journa l h om epa ge : ht tp : / /www.e lsev ier .com/ locate / t rprotditorial
he art  of  proteomics  translation
ity of their universities or hospitals. Translational researcherss we  celebrate the start of 2013, I am pleased to announce the
rst publications in our newly  launched journal, Translational
roteomics. This has been made possible thanks to Elsevier’s
trong support and the enthusiastic participation of the Jour-
al’s Associate Editors and Editorial Board members.
Over the years, the difﬁculties of transferring fundamen-
al proteomics discoveries to clinical applications have caused
 lot of frustration to proteomics researchers and clinicians
like, in both academia and industry. One of the reasons for
his barrier is the lack of understanding between basic scien-
ists and physicians: they have been trained using opposing
oncepts. Whilst the former want to control and understand
ll variables, the latter need rapid actions on patients, rather
han absolute certainties. Both disciplines are difﬁcult to con-
ense into a single scientist and therefore interdisciplinary
ssociations need to be fostered.
Translational research has often been viewed as a two-
ay street: bedside to bench, and back to bedside. We should
erhaps look at it as a roundabout, with the patient and his
isease in the centre, surrounded by a constant, iterative inter-
lay between basic, translational and clinical scientists, from
oth the public and private sectors. Proteomics research needs
ore  than just a translation road bridge from discoveries to
ures. Rather, it requires networks of road junctions to ﬁll all
he gaps and to allow cross-fertilization and synergies.
Translational research and translational proteomics are
ore than just interesting concepts and hot keywords, they
re supposed to improve the quality of people’s lives. With
he launch of Translational Proteomics,  we  want to help the sci-
ntiﬁc and medical communities overcome the challenges on
he long path from discovery to patient care. By focusing on
onnecting basic proteomics research to its ultimate clinical
pplications, the Journal will provide a space for publica-
ions detailing proteomics experiments, from early discovery
o validation and the bedside.
Translational Proteomics’  uniqueness resides in its intent to
ublish multi-disciplinary studies as single papers, with noloss of information – studies that today would most likely be
broken up into two or three separate papers. The Journal cov-
ers all areas of human proteomics using multi-disciplinary
approaches to untangle complex disease processes. Emphasis
is clearly placed on linking basic science to clinical research,
for the rapid dissemination of novel discoveries. A special
effort will be made to favour the acceleration of the dis-
covery, development and validation of biomarkers associated
with multifactorial human disorders. This will aid the earliest
possible diagnosis, stratiﬁcation, prognosis and monitoring of
diseases, and the prediction of drug responses.
Understanding of human diseases is still very limited
because scientists have been confronted with some enor-
mous challenges, such as wide genetic polymorphism, an
extremely large heterogeneity of diseases (e.g., diabetes, can-
cer, infections), as well as strict societal constraints (ethics,
funds, time). Why do two patients with the same disease,
and identical clinical and laboratory parameters, respond dif-
ferently to the same treatment? Why do they experience
different side effects? This complexity has led many  scientists
to use animal models to predict drug outcomes, mimicking
human diseases as much as possible, but simplifying the bio-
logical background. These models are priceless sources of
information, but unfortunately many  such “unpolluted” stud-
ies fail when applied to humans. As a result, today we  know
much more  about effective treatments of human diseases on
mouse models than on humans themselves. This highlights
the species-speciﬁc properties and the huge diversity in bio-
logical systems.
Most scientists performing basic science today would like
to bring their biomedical discoveries to as many  patients as
possible. However, the important clinical development needed
to push such studies to larger trials, is often beyond the capac-can better get their ﬁndings to the bedside by working with
pharmaceutical and biotechnology companies. Pharmaceuti-
cal companies’ drug development pipelines in therapeutics
o t e o2  t r a n s l a t i o n a l p r 
and diagnostics are drying up; they are ready for the push
towards more  translational research, to both catalyse, and be
a part of medical applications of basic biomedical research.
Being at the boundary of traditional and emerging disciplines
– through interdisciplinary projects and groups of scientists –
should be the rule and not the exception. These are the road
junctions to cross-fertilization and synergies.
Translational Proteomics is thus intended for academic,
industrial and clinical researchers, physicians, pharmaceu-
tical scientists, biochemists, clinical chemists, and disease
molecular biologists in the ﬁelds of applied human pro-
teomics. Examples of diseases include oncology, neurology,
immunology, cardiovascular diseases, infectious diseases
and any internal medicine disorder. Several special sections
will also be highlighted, such as Systems Biology and Inte-
grative Bioinformatics, Clinical Proteomics and Personalised
Medicine, Comparative Proteomics and Drug Development,
Medical Bioinformatics and Biostatistics, and ﬁnally Food and
Health. A team of internationally renowned experts in both
the basic and clinical aspects of human sciences, and covering
most of the above areas, have accepted the invitation to join
the board as Associate Editors. I am delighted to have Dolores
Cahill (Autoimmunity/Cancer/Microarray), Charles Pineau
(Reproduction), Salvatore Sechi (Diabetes), Peter Bergsten
(Obesity), Joan Montaner (Cerebrovascular diseases, Neurol-
ogy), Pierre Fontana (Hematology/Angiology/Cardiology) and
Kevin Wang (Brain) working with me  setting the directions of
the journal. m i c s 1 ( 2 0 1 3 ) 1–2
Translational Proteomics is an online-only, open access jour-
nal. Authors will retain copyright and are offered the choice
of Creative Commons licenses. The journal publishes original
research manuscripts after a rigorous peer-review process to
ensure excellence in human investigations. It also publishes
opinions and reviews.
Finally, I would like to take this opportunity to express my
thanks to all the members of our newly constituted editorial
board. Together we are embarking on an exciting adventure
in the development and promotion of Translational Proteomics.
The art of translation is becoming increasingly multifaceted
and complex, and all the participants in our journey urgently
need to think outside their own box of test tubes. The mem-
bers of the editorial board all strongly believe that, as a part
of the broad biomedical community, it is our social duty and
responsibility to make translation a reality.
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